

## JHC's Clinical Study published in one of most cited scientific journals

- A peer reviewed article covering the Joondalup Health Centre (JHC) clinical study, has been published in Obstetrics & Gynecology; the official publication of the American College of Obstetricians and Gynecologists
- Known as 'The Green Journal', Obstetrics & Gynecology has been widely regarded as one of the most renowned scientific journals since first published in 1953, now reaching 40,000 subscribers globally
- The article, entitled '*Accuracy, Clinical Utility, and Usability of a Wireless Self-Guided Fetal Heart Rate Monitor*', provided a detailed overview of the 2020 clinical study results, and is expected to increase awareness of the HeraCARE platform and HeraBEAT device amongst key opinion leaders globally
- The article concluded that HeraBEAT was accurate and easy for clinicians and participants to use and had potential to be used in telehealth consultations
- The scientific credibility afforded by HeraMED's inclusion in this journal is anticipated to generate significant international exposure and underpin new partnership opportunities

**HeraMED Limited (ASX:HMD)** ("HeraMED" or the "Company"), a medical data and technology company leading the digital transformation of maternity care, is pleased to announce the publication of the clinical study results from the Joondalup Health Centre (JHC) in a globally recognised scientific journal 'Obstetrics & Gynecology'.

The article included the following conclusion:

*The heartbeat monitor was accurate and easy for clinicians and participants to use. Data recorded at home were equivalent to those obtained using current assessment protocols for low-risk pregnancies, potentially allowing the device to be used in telehealth consultations.*

On 8 October 2020, HeraMED announced outstanding results from a clinical study undertaken by JHC that delivered clinical and functional validation of the HeraBEAT device. The accuracy of the HeraBEAT device was found to be excellent when compared to the industry gold standard CTG (Phillips Avalon) machine. The Foetal Heart Rate (FHR) was detected on 100% of occasions by clinicians and importantly, the FHR was detected on 100% of occasions by the expectant mothers when using the device without assistance.

**HeraMED CEO and Cofounder Mr David Groberman**, said: "I would like to congratulate Dr. Paul Porter and the research team for this publication which represents important scientific credibility for our technology. The publication of this article represents an endorsement of the 2020 JHC clinical study results and we are delighted that the outstanding results will now be brought to the attention of key opinion leaders globally, in the fields of obstetricians and gynaecologists.

"Obstetrics & Gynecology represents one of the most highly cited journals, with an impact factor of 5.5, which places it in the top 7% of all scientific journals. Research for this journal undergoes an extremely rigorous peer review process and is considered the highest quality. This article, appearing in such a highly cited scientific journal represents an important achievement for HeraMED and will represent an effective marketing tool as we continue to capitalise on the growing pipeline of new partnership opportunities."

**About the Obstetrics & Gynecology Scientific Journal**

Obstetrics & Gynecology is the official publication of the American College of Obstetricians and Gynecologists (ACOG). Popularly known as "The Green Journal," Obstetrics & Gynecology has been published since 1953. The goal of the journal is to promote excellence in the clinical practice of obstetrics and gynecology and closely related fields. To do so, the journal publishes articles on a variety of translational and clinical topics. Obstetrics & Gynecology reaches over 45,000 members and non-member subscribers.

**About HeraMED's commercialisation strategy**

The HeraBEAT device forms the backbone of HeraMED's comprehensive HeraCARE SaaS and IoT platform, a digital hybrid maternity care solution. HeraMED's proprietary technology has already obtained TGA (Australia) and CE (Europe) approvals for OTC (over the counter) home use as well as FDA 510K clearance for home use under prescription in the US.

The onset of COVID-19 has presented a unique opportunity globally to fast-track adoption of digital health in maternity care. HeraMED is well-placed to deliver high-quality, prenatal, and postpartum care to improve the safety, efficiency, and cost of maternal healthcare. HeraMED continues to receive significant interest from prospects from around the world and is focused on progressing the growing pipeline of potential partnerships.

The full article is available by clicking this link:

[https://journals.lww.com/greenjournal/Fulltext/9900/Accuracy,\\_Clinical\\_Utility,\\_and\\_Usability\\_of\\_a.143.aspx](https://journals.lww.com/greenjournal/Fulltext/9900/Accuracy,_Clinical_Utility,_and_Usability_of_a.143.aspx)

**-ENDS-**

This announcement has been authorised by the Board of HeraMED Limited.

**HeraMED Limited**

CEO and Co-Founder

David Groberman

M: +972 52 6991188

E: [David@hera-med.com](mailto:David@hera-med.com)

**Company Secretary**

Jonathan Hart

T: +61 2 8379 2961

E: [Jonathan@hera-med.com](mailto:Jonathan@hera-med.com)

**Media Enquiries**

Melissa Hamilton

Media & Capital Partners

M: +61 4 1775 0274

E: [Melissa.hamilton@mcpartners.com.au](mailto:Melissa.hamilton@mcpartners.com.au)

**About HeraMED Limited (ASX:HMD):**

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data and a digital social networking dashboard.

**About HeraCARE**

The Company's proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.